Company intelligence / Profile preview
Oxagen
Milton Park / Abingdon, Oxfordshire/England, United Kingdomoxygen.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Oxagen was a UK-based biotechnology company specializing in the identification of novel drug targets using human genetics, with a particular emphasis on inflammatory diseases and women’s health. The company advanced several programs into preclinical and early clinical development but did not bring any products to market before ceasing operations.
- Therapeutic areas
- Women's HealthEndocrinologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Historically partnered with major pharmaceutical companies such as Schering AG for osteoporosis research.
Beyond the preview
Go deeper on Oxagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxagen.